A Faster Way to Detect One Key Autoantibody in Type 1 Diabetes

In the months and years before type 1 diabetes develops, the immune system begins attacking the insulin-producing beta cells in the pancreas. This attack is signaled by the presence of autoantibodies—proteins the immune system makes against its own tissues. One of the most important of these markers is anti-IA2 (short for insulinoma-associated antigen 2). Detecting anti-IA2 helps doctors confirm a type 1 diabetes diagnosis and estimate a person's risk of developing the disease.

Currently, identifying these autoantibodies relies on tests that may be slow, require manual processing, or are not widely available. Researchers have developed a new automated test designed to make screening faster and easier for clinical laboratories.

Scientists tested a newly developed anti-IA2 ELISA from Euroimmun—a test that is approved for use in Europe and designed to work automatically on laboratory equipment. The test was evaluated using blood samples from people recently diagnosed with type 1 diabetes (median age 11 years), adults with latent autoimmune diabetes, and people without diabetes. Researchers also used standardized reference samples provided by the Islet Autoantibody Standardization Program to ensure accuracy across different labs.

The test was checked for precision (how consistent results are from run to run), sensitivity (ability to correctly identify people who have the autoantibody), specificity (ability to correctly identify people who don't have it), and how well it performed across a wide range of antibody levels.

The new test showed excellent reliability. Results were highly consistent from test to test, with variability of 3.2% or less. The test reliably detected even small amounts of anti-IA2 and performed well across the full range of measurement levels tested.

When applied to people with type 1 diabetes, the test correctly identified anti-IA2 in 53.8% of cases overall, and in 56.5% of newly diagnosed patients. In standardized reference samples, it correctly identified the autoantibody in 76% of cases. The test correctly ruled out anti-IA2 in 98.4% of people without type 1 diabetes, meaning false alarms were rare.

The new test performed very similarly to an older version and showed strong agreement with a radioimmunoassay, another method used to detect anti-IA2. The test also remained reliable even when blood samples had unusual appearance or composition.

The new automated test offers practical advantages: it can run on standard laboratory equipment, produces reliable results, and rarely produces false positives. These features could make anti-IA2 screening more accessible in clinical labs that currently do not offer it.

It is important to note that no single autoantibody test catches all cases of type 1 diabetes. Most people diagnosed with type 1 have multiple autoantibodies present at the time of diagnosis. Anti-IA2 is one piece of a larger diagnostic picture. The moderate sensitivity of this test (meaning it may miss some people who have anti-IA2) underscores why comprehensive screening often includes testing for multiple autoantibodies rather than relying on a single marker.

Source: Clinica chimica acta; international journal of clinical chemistry. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.